If Stéphane Bancel ever questioned his ability to move markets, he got his answer last week. The Moderna CEO’s observation that existing vaccines will be less effective at tackling Omicron than earlier strains of Covid-19 rattled investors sufficiently to spark another global lurch downwards, says the Financial Times. The mood has since lightened – there are signs the variant may prove less serious than feared. But Moderna and other vaccine-makers still have their work cut out. Bancel reckons Moderna could make between two and three billion Omicron-targeted doses next year, but it’s a balancing act. “It would be risky,” he says, to shift the entire production capacity into the fight when other variants are still in circulation.
At the vanguard of science
Moderna is now such a household name that it’s almost a shock to recall that its sole commercial product is the Covid-19 vaccine. “Before the pandemic, Moderna was simply a heavily loss-making biotech with unproven technology,” says The Sunday Times. But delivery of its mRNA jab “has cemented its place at the vanguard of scientific discovery”. It has also made a small fortune for Bancel, who owns around 8% of the Cambridge, Massachusetts-based outfit’s shares, which have jumped by more than 1,000% since it floated on Nasdaq in 2018. In just over a decade since Moderna was founded – on the-then radical hunch that mRNA could be used to treat cancer, diabetes and genetic diseases – its market value has shot up to nearly $115bn. As a peer observes: “The pandemic came almost as a blessing to prove the technology”.
According to early investor Baillie Gifford, the pugnacious Frenchman has always stood out from the crowd as “a relentless risk optimiser”. Bancel famously quit a “safe job”, as CEO of the French diagnostics multinational BioMérieux, to join the fledgling Moderna in 2011 – telling his photographer wife, Brenda, there was just a 5% chance that its “crazy idea” would work. As he observed on a recent Distillations podcast, he couldn’t forego the “chance of changing medicine forever”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The emperor was clothed
Born in 1972, Bancel grew up in Marseilles, the son of an engineer and a doctor – fusing these professions into his own life when he chose to study biomolecular engineering at École Centrale in Paris. His subsequent move to Minnesota for a masters opened up the world of US business. Bancel’s first job was at BioMérieux, which had sponsored his MBA at Harvard. At 29 he joined the US drug-maker Eli Lilly, before returning to lead BioMérieux when he was just 34.
In Moderna’s early days, cash was so tight it often struggled to keep the lights on for six months at a time. Bancel, who had “an almost messianic reverence for the mRNA technology”, took an all or nothing approach: you either got with the plot, or you were out, noted industry journal Stat in 2016. Reports of conflicts and defections multiplied – even as Bancel succeeded in persuading the industry’s big-hitters of Moderna’s potential (forging a transforming $240m partnership with AstraZeneca in 2013). He later consulted the HR departments of some tech firms for “tips on employee retention”. The charge of scientific critics back then was that Moderna was “a case of emperor’s new clothes”. Whatever Bancel’s current challenges, he has been vindicated. As the world queues up for Moderna shots, you don’t hear much talk of naked emperors.
-
Dividend heroes: the investment trusts that have increased their dividends for 20+ yearsInvestment trusts can be a good option for income-focused investors – but which trusts have consistently increased their dividends over the past 20 years?
-
Six reasons not to top up your state pensionA deadline to buy National Insurance credits and top up your state pension is fast approaching. Here’s why it may not be worth it for some people
-
Europe prepares to stand alone as Trump turns on UkraineSupport for old military alliances is wavering in the US under Donald Trump. Europe’s leaders are rushing to fill the void. Simon Wilson reports
-
Volodymyr Zelenskyy moves to appease Donald Trump – what happens now?Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
-
Kirill Dmitriev: from Wall Street banker to Putin’s emissary to TrumpworldProfile Kirill Dmitriev is a product of America’s finest institutions and has emerged as the Russian president’s point man in negotiations with Donald Trump
-
Key takeaways from the 2025 German election resultsFriedrich Merz heralds a new era for Germany, after the German elections revealed a majority of young voters are leaning towards the far-right
-
Is Rachel Reeves leading the UK to a spring crisis?Opinion Rachel Reeves is sleepwalking into an economic catastrophe of her own making. Don’t expect a change of direction, says Matthew Lynn
-
Aga Khan, spiritual leader and billionaire investor, dies at 88The Aga Khan was a religious leader to millions of Shia Ismaili Muslims and a billionaire investor with a love of horses. He saw no contradiction in his roles
-
Will Labour rethink the Chagos Islands deal with Mauritius?Labour hailed its agreement to hand control of the Chagos Islands to Mauritius as a diplomatic coup. The reality is more woeful, says Simon Wilson
-
No need to run from the robots: Nobel laureate Daron Acemoglu talks to MoneyWeekInterview Daron Acemoglu, Nobel Prize winner and professor at MIT tells Matthew Partridge why the gains from AI have been overhyped
